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HE relative roles of genetic constitution and en-
vironmental exposure in the causation of cancer
have been debated for decades.
 
1
 
 Geographic differ-
ences, trends over time in the risk of cancer, and de-
tailed studies of migrant populations overwhelming-
ly implicate environmental exposures as major causal
factors and often identify the responsible carcinogens
(e.g., tobacco, alcohol, radiation, occupational toxins,
infections, diet, drugs). From this work has come the
widely accepted estimate that 80 to 90 percent of hu-
man cancer is due to environmental factors.
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 Yet in
the past 15 years, the explosion of molecular genet-
ics has overshadowed environmental explanations by
revealing genetic mechanisms underlying cancer. This
is why the current confusion about environmental and
genetic risk factors for cancer — on the part of pa-
tients, their families, clinicians, researchers, public pol-
icy makers, and the general public — is not surprising.
The gold standard for distinguishing genetic from
environmental traits has been the study of twins.
Comparing the incidence of disease in unrelated peo-
ple, fraternal twins, and identical twins allows the
heritable and environmental components of risk to be
estimated. The study described by Lichtenstein and
his colleagues in this issue of the 
 
Journal
 
3
 
 has several
advantages over previous studies of cancer in twins.
It is population-based, the outcomes are derived from
complete data on incidence, and the size of the pop-
ulation studied is four times as great as in any previ-
ous effort.
Although the current study has many strengths,
its weaknesses illustrate the difficulties of using data
on twins in studies of cancer. The study included
more than 10,000 cancers in a total population of
nearly 90,000 twins in Scandinavia, but the data ef-
fectively address cancer at only the four or five most
common anatomical sites — and even for some of
these, without much precision. The confidence in-
tervals for the heritable proportion of susceptibility
to stomach, colorectal, breast, and lung cancer all
extend roughly from 5 percent to 50 percent, a fairly
large range. The study lacks information on screening
practices, which is quite possibly an issue in studies
of twins. It also lacks data on specific types of expo-
sure (e.g., tobacco use), so issues of interactions be-
tween genes and environment cannot be addressed.
Indeed, the statistical model used specifically assumes
no such interactions, ensuring that if any do exist, they
will probably show up partly in the estimated envi-
T
 
ronmental component of risk and partly in the her-
itable component. These practical limitations are in-
herent in studies of cancer in twins, and they indicate
that delineation of the specific environmental and ge-
netic components of the risk of cancer is likely to de-
pend on the emerging new generation of large molec-
ular epidemiologic studies — both population-based
and family-based — rather than on studies of twins.
Despite its limitations, the study by Lichtenstein
et al. provides new and valuable information for the
nature-versus-nurture debate. In general, environmen-
tal factors were the dominant determinants of the site-
specific risk of cancer. For cancer at four of the five
common anatomical sites, estimates of the proportion
of risk due to environmental effects were all 65 per-
cent or greater. Though considerably less precise, es-
timates of the proportion of susceptibility that was
due to environmental factors were generally even
higher for cancer at the six next most frequent sites
studied. These findings are consistent with the con-
clusions of studies of migrant groups. For example,
rates of breast cancer among women who have recent-
ly immigrated to the United States from rural Asia
are similar to those in their homelands and about 80
percent lower than the rates among third-generation
Asian-American women, who have rates similar to or
higher than those among white women in the Unit-
ed States.
 
4
 
 This pattern is entirely consistent with
the estimates by Lichtenstein et al. in this study that
73 percent of the causation of breast cancer is envi-
ronmental and 27 percent heritable, particularly if a
portion of the effect of heritable factors relates to
genetic modification of environmental risk factors.
Although environmental effects may predominate,
the findings with regard to heritability are notewor-
thy. Rates of concordance were generally higher in
monozygotic pairs of twins than in dizygotic pairs,
and the estimates of the proportion of susceptibility
to cancer that was due to heritable effects ranged
from 26 percent to 42 percent for cancer at the five
common sites. These are substantial burdens of can-
cer risk, and substantially higher than estimates of
risk based on a family history of a particular cancer.
This degree of influence is also what would be ex-
pected if genetic effects are not limited to the rare,
highly penetrant mutations that can result in familial
cancer, but are also the result of polymorphisms that
carry a much lower level of risk, do not result in an
excess of cancer in families, and are much more prev-
alent than highly penetrant mutations in the general
population. The most noteworthy effect of heritable
factors is clearly that identified for prostate cancer
(42 percent of risk). Like the other common cancers,
prostate cancer shows marked international variation,
and the risk among migrant groups tends to rise to-
ward the level in the adopted country over several
generations, indicating a substantial environmental
component of the risk of this cancer.
 
5
 
 Nonetheless,
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a number of large-scale studies have searched for risk
factors for prostate cancer and have found few. This
lack of evidence stands in stark contrast to the situa-
tion with respect to breast, lung, and stomach cancer,
for example, for which such studies have identified a
variety of lifestyle-related, infectious, reproductive, and
other environmental factors that are associated with
moderate-to-high levels of risk. Perhaps prostate can-
cer does have a greater heritable component than can-
cer at these other sites. If some of the inherited fac-
tors are involved in modifying the risk associated with
environmental factors, then success in identifying
these two kinds of influences may depend on direct
exploration of interactions between genes and envi-
ronment.
The estimates of absolute concordance are telling.
For cancer at the common sites in monozygotic twins,
the rate of concordance is generally less than 15 per-
cent. Thus, the fatalism of the general public about
the inevitability of genetic effects should be easily
dispelled. There is a low absolute probability that a
cancer will develop in a person whose identical twin
— a person with an identical genome and many sim-
ilar exposures — has the same type of cancer. This
should also be instructive to some scientists and oth-
ers interested in individual risk assessment who be-
lieve that, with enough information, it will be pos-
sible to predict accurately who will contract a disease
and who will not. With a few rare exceptions, any
such deterministic approach to a disease as multifac-
torial as cancer seems doomed, and the data on twins
seem to confirm that. This lack of absolute predict-
ability, too, should not be surprising, given what we
know about the risk of second primary cancers in
paired organs.
 
6
 
 For example, a woman’s average an-
nual risk of a contralateral breast cancer after the di-
agnosis of a first primary breast cancer is about 0.8
percent
 
7,8
 
 — and this risk is for a person with, obvi-
ously, not only the identical genome, but also the
identical complex of exposures.
Several things seem clear with respect to the im-
portance of genetic and environmental factors in the
causation and control of cancer. First, knowledge of
one should expand our knowledge of the other. In-
formation about types of environmental exposure that
affect the risk of cancer should point to genes that
might modify this risk, and the identification of genes
associated with risk could help to indict previously
unrecognized environmental risk factors.
 
9
 
 Second,
when genes and environment interact to produce a
risk greater than the sum of their independent ef-
fects, this interactive component can be eliminated
by removing either the genetic or the environmental
factor. Finally, for cancer at many sites there are lim-
ited effective options for prevention. For this reason,
unique opportunities to expand our knowledge of risk
factors should be exploited regardless of their source.
Perhaps it is time to drop the competition implied
by talking about a debate over nature versus nurture
in favor of efforts to exploit every opportunity to
identify and manipulate both environmental and ge-
netic risk factors to improve the control of cancer.
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HE promise of bioengineered replacements for
diseased or damaged tissues has become a reality,
notably for skin and cartilage. The article by Tsai et
al. in this issue of the 
 
Journal
 
1
 
 demonstrates the prom-
ise of a nascent form of technology that may provide
a new tool for reconstructing damaged ocular sur-
faces that previously would have been unrepairable.
Conditions such as the Stevens–Johnson syndrome,
cicatricial pemphigoid, and chemical burns, among
others, can severely compromise ocular surfaces and
cause catastrophic visual loss in otherwise healthy eyes;
such problems afflict thousands of patients in North
America every year.
 
2
 
 The global burden of blindness
from these disorders is probably much greater be-
cause of the many cases of trachoma and the higher
incidence of trauma outside the United States and
Canada. A common pathogenic feature of this seem-
ingly diverse group of disorders is the depletion of the
stem-cell population responsible for repairing the
damaged corneal epithelium.
T
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Conventional corneal transplantation is simply not
successful in patients with this type of chronic surface
problem. The donor corneal epithelium is gradually
replaced, and the remaining transplanted corneal stro-
ma, which is immunologically nonreactive, must ul-
timately be resurfaced with epithelial cells derived
from the recipient’s corneal stem cells. An absence
or deficiency of stem cells allows, or may even stim-
ulate, conjunctival-cell ingrowth and its accompany-
ing neovascularization and inflammation, resulting
in failure of the corneal graft. Therapies aimed at re-
plenishing the stem-cell population have evolved in
tandem with increased knowledge of the biology of
corneal stem cells.
As with other self-renewing epithelial tissues, the
corneal epithelium is maintained by an ordered, hi-
erarchical replication of stem cells, which reside in the
basal layer of the limbus.
 
3
 
 It is clear from both ex-
perimental studies and studies of human ocular dis-
orders that depletion of the limbal stem-cell pool re-
sults in an abnormal corneal surface, which cannot be
normalized without the introduction of a new source
of stem cells. The most direct approach to correcting
corneal-surface disease due to stem-cell deficiency has
been transplantation of a segment of the stem-cell–
laden limbus, either as a contralateral autograft or,
more recently, as an allograft from either a cadaveric
donor or a living relative.
 
2
 
 However, this procedure
requires the harvest of approximately half (or more)
of the limbus, and the procedure therefore jeopar-
dizes the donor eye, whether the transplant is autol-
ogous or allogeneic.
 
4
 
 An ideal approach would use a
bioengineered replacement tissue that replenished the
pool of stem cells without endangering the corneal
stem cells of the donor eye.
To engineer a successful replacement tissue, it is
necessary to provide an ex vivo environment for stem
cells that maintains both the replicative function of
the tissue and its differentiated phenotype. However,
it is also necessary to create a biologically compatible
scaffold or stroma for the tissue. Tsai and colleagues
 
1
 
chose human amniotic membrane as the scaffold on
which to grow their replacement corneal surface. That
was a logical choice, given the already widespread use
of human amniotic membrane for ocular-surface re-
construction.
 
5
 
 Numerous studies (reviewed in the ar-
ticle by Tsai et al.) have demonstrated that amniotic
membrane facilitates epithelialization without allow-
ing fibrovascular growth, supports epithelial-cell dif-
ferentiation, is gradually resorbed in vivo, is nonanti-
genic, and contains extracellular-matrix components
resembling those of conjunctival basement membrane.
Indeed, the successful outcomes in the patients
into whose eyes Tsai et al. transplanted limbal epi-
thelial cells cultured on amniotic membrane, as well
as the patients who underwent a similar procedure
in our own study,
 
6
 
 suggest the promise of the tech-
nique for patients with limbal stem-cell deficiency or
disease. An advantage of the procedure is the reduc-
tion in the amount of donor limbal tissue required
(2 mm
 
2
 
 in both studies), which minimizes the pos-
sibility of damage to the donor eye. Combining the
expansion of cells ex vivo with cultivation on a mod-
ified amniotic membrane has the advantage of ensur-
ing a compatible extracellular matrix for the graft,
thus increasing its durability and manipulability. This
method is an advance over earlier attempts at the use
of engineered corneal surfaces, in which fragile sheets
of epithelial cells, with no substantial underlying stro-
mal support, were transplanted.
 
7,8
 
Despite the promise of the procedure described
by Tsai et al., challenges lie ahead. The difficulty re-
mains of identifying stem cells and ensuring that
enough of them are present in the bioengineered tis-
sue to repopulate the ocular surface. Current tech-
niques for identifying corneal stem cells rely on their
ability to take up various substances or to serve as
progenitor cells for large colonies in culture — char-
acteristics difficult to identify once the cells have been
incorporated into a tissue prepared for human trans-
plantation. The identification of cell-surface markers,
such as those identified for keratinocyte stem cells,
 
9
 
will help address this issue. A second challenge is to
optimize the scaffold on which the replacement cor-
neal surface is grown. Although amniotic membrane is
currently the most widely used material for this pur-
pose, a bioengineered laboratory equivalent for use as
corneal stroma would minimize the possible risk, al-
beit remote, of the transmission of an as-yet-uniden-
tified infectious disease through use of an allograft.
In addition, the persistence of transplanted donor
stem cells, and their reintegration into the limbus of
the recipient eye, have yet to be demonstrated in pa-
tients who have received bioengineered grafts. This
issue is particularly important if the future of bioengi-
neered corneal-surface tissue lies with allogeneic do-
nor cells. Although the persistence of donor-specific
DNA sequences has been detected as long as 30
months after conventional transplantation of alloge-
neic limbal tissue,
 
10
 
 no such analyses have been per-
formed in recipients of bioengineered grafts. Evalu-
ation of bioengineered composite skin grafts has
revealed that, despite the long-term persistence of the
allogeneic epithelial cells, the donor cells are slowly
replaced by host cells. This finding suggests that, in
some cases, the cultured allogeneic graft acts as a bi-
ologic dressing, providing the cytokines and growth
factors required for tissue repair in the appropriate
temporal sequence. Finally, answering the question
of what will happen to the tissue or organ decades
after it is implanted will require years of careful ob-
servation and follow-up.
Bioengineered or cultured tissue products are cur-
rently being produced to replace other tissues, and
the progress with corneal-surface replacement indi-
cates that such products are likely to revolutionize
The New England Journal of Medicine 
Downloaded from nejm.org at UQ Library on March 30, 2017. For personal use only. No other uses without permission. 
 Copyright © 2000 Massachusetts Medical Society. All rights reserved. 
 138
 
·
 
July 13, 2000
 
The New England Journal  of  Medicine
 
the treatment of many epithelial and even visceral dis-
eases. Heartened as we should be by the rapid progress
in this area, we must recognize that there is still much
to be learned before bioengineered organs will be
routinely available.
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MERGENCY physicians have traditionally relied
heavily on diagnostic imaging in the evaluation
of patients with head or neck trauma. This conser-
vative approach is intended to reduce the risk of miss-
ing intracranial lesions or cervical-spine fractures to
virtually zero, since the morbidity associated with
these injuries can be great and the medicolegal con-
sequences severe. Each year in the United States more
than 2 million adults present on an emergency basis
after trauma to the head. Of the 80 percent with ap-
parently minor injury,
 
1
 
 between 6 percent and 9 per-
cent harbor unexpected, traumatic intracranial lesions,
although fewer than 1 percent require neurosurgical
intervention.
 
2,3
 
 Approximately 800,000 radiographs
of the spine are obtained annually because of poten-
E
 
tial cervical-spine trauma.
 
4
 
 Spinal cord injuries occur
in about 10,000 patients per year, and more than
half of these injuries involve the cervical spine.
 
5
 
 Op-
timally, diagnostic imaging of patients with head or
neck trauma should be performed selectively, but with
the ability to detect potentially devastating lesions.
Most recommendations for the use of computed
tomography (CT) in patients with minor head inju-
ries and plain radiography in those with potential
cervical-spine injuries have been extremely cautious.
However, these recommendations have been based
mainly on findings in patients seen in consultation
or admitted for surgical or neurosurgical care rather
than on findings in the majority of patients, who are
screened for injury and treated after the trauma by
emergency physicians.
This issue of the 
 
Journal
 
 includes two studies with
compelling data that should assist emergency physi-
cians in identifying patients at low risk after minor
head or neck trauma. Each study group sought to
determine whether the number of unnecessary diag-
nostic imaging tests can be reduced through the adop-
tion of a defined set of clinical criteria that has been
validated for use in patients in the emergency depart-
ment. Both sets of criteria were developed to address
the clinically relevant question not of who requires
imaging but, rather, of who does not.
Haydel et al.
 
6
 
 ask whether the use of CT can be
avoided in patients with apparently minor head inju-
ry who present within 24 hours after blunt trauma.
In their population of patients at least three years
old, minor head injury was defined by a loss of con-
sciousness and, on arrival at the emergency depart-
ment, a score on the Glasgow Coma Scale of 15 and
normal findings on a brief neurologic examination.
Only 57 of 909 patients who met the inclusion cri-
teria (6.3 percent) had positive findings on CT. All
57 patients had at least one of seven clinical features:
headache, vomiting, age greater than 60 years, drug
or alcohol intoxication, deficits in short-term mem-
ory, trauma above the clavicles, and post-traumatic
seizure. Most of the findings were broadly defined;
that is, any history or evidence of headache, vomiting,
craniofacial trauma, or seizure was deemed sufficient.
Most important, all 212 patients with none of these
seven features (23 percent) had normal CT scans.
Hoffman and colleagues
 
7
 
 posed a similar question:
Under what circumstances after blunt trauma is stand-
ard three-view cervical-spine radiography unneces-
sary? This enormous study at 21 centers included
34,069 patients. The five criteria for a low risk of in-
jury were based on previous work
 
4
 
: no midline cer-
vical tenderness, no focal neurologic deficit, normal
alertness, absence of intoxication, and no painful, dis-
tracting injury. A total of 818 patients had cervical-
spine injuries (2.4 percent of the study population).
Of these 818 patients, only 8 fulfilled all the criteria
for a low risk of injury (false negative rate, 1.0 per-
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cent). In six of these patients, the injuries were clin-
ically insignificant, since they required no specific
management. Only the remaining two patients were
categorized as having clinically significant injuries
according to predefined criteria. However, one had a
lesion that may have been an old injury, and the oth-
er was probably misclassified as not having a distract-
ing, painful injury and thus did not in fact satisfy all
the criteria for a low risk.
These two clinical decision rules share a number
of noteworthy features. Both deal with common and
extremely expensive clinical problems. The percent-
age of negative diagnostic studies is tremendous, as in-
dicated by the 95.7 percent and 97.6 percent rates of
negative studies in the cohorts screened for cervical-
spine injury and minor head injury, respectively. These
investigations were methodologically sound. Each was
prospective and used a standardized data-collection
instrument. The two clinical decision rules are sim-
ple, brief, and pragmatic, with only five and seven
clinical features to evaluate. They can be learned with
minimal instruction and can be applied consistently,
as shown by the acceptably low rates of interobserver
variability. Each rule relies on mostly qualitative as-
sessments that can be made rapidly at the bedside and
are therefore practical in the emergency setting. In
addition, these studies were designed to ensure pa-
tients’ safety; if there was any pathologic finding, the
CT scan of the head was considered positive, wheth-
er or not it led to any change in treatment. More-
over, clinical significance was conservatively defined.
Both rules could save far more than money. Un-
needed diagnostic examinations are inconvenient, un-
comfortable, and potentially unsafe for patients. They
waste time, space, and the effort of skilled person-
nel. As a direct result, time spent in busy emergency
departments increases, and patients’ satisfaction de-
clines. Finally, failure to diagnose clinically significant
head or neck lesions could have consequences so grave
that only an exceptionally sensitive rule would be ac-
ceptable to clinicians. In fact, the negative predictive
values of the criteria used to rule out minor, closed
head injury and cervical-spine injury in these studies
were 100 percent and 99.8 percent, respectively, with
impressive confidence intervals as a result of the large
numbers of patients evaluated, particularly in the
study of cervical-spine injury.
These studies, while remarkable, are not without
precedent. Other investigations in emergency depart-
ments have led to decreased use of expensive or lim-
ited resources in the evaluation of patients with trauma
who have a low risk of injury. For instance, clinical
decision rules formulated by Stiell et al. and Plint et
al. and developed and tested in emergency depart-
ments have succeeded in greatly reducing the num-
ber of radiographs obtained in the emergency eval-
uation of adults and children with knee injuries
 
8
 
 or
ankle injuries.
 
9,10
 
 Although emergency departments
can be chaotic, it is now routine for well-controlled,
prospective, randomized trials to be conducted in
them. Indeed, for rigorous testing of the initial man-
agement of limb-threatening and life-threatening con-
ditions, the emergency department should be consid-
ered the essential laboratory for clinical research.
What, then, are the next steps? The study by Hoff-
man et al. was large and was undertaken at multiple
centers. The decision rule that it examined for ruling
out cervical-spine injury can be adopted with great
confidence in most clinical settings. This study re-
inforces the empirical sense of many emergency phy-
sicians and should reassure clinicians who, on the basis
of previous work, have already cautiously adopted sim-
ilar guidelines. The data in the study by Haydel et al.
come from a smaller cohort at a single site and cannot
be considered quite as convincing. Corroborative in-
vestigations may be needed before conservative cli-
nicians will implement the decision rule for minor,
closed head injury. For both these problems, prospec-
tive validation studies with follow-up are needed but
will require a great expenditure of time and enormous
resources. Further research may refine the rules and
extend their use to practice by nurses and paramedics.
These two valuable clinical decision rules can di-
minish the imperative for health care providers to seek
diagnostic perfection. The beauty of these instru-
ments is their ability to identify, on the basis of clin-
ical evaluation alone, patients who have a low risk of
serious injury. Their application should provide ben-
efit to patients, providers, and insurers. Certainly, iso-
lated exceptions to these rules are bound to occur.
However, the high-quality data from which these
rules are derived should be reassuring to patients and
physicians and persuasive to the health care industry
and the medicolegal system.
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WILL GENETICS REVOLUTIONIZE 
MEDICINE?
N both sides of the Atlantic, revolutionary claims
have been made about the ultimate impact of
genetics on clinical medicine. John Bell at Oxford has
asserted that “within the next decade genetic testing
will be used widely for predictive testing in healthy
people and for diagnosis and management of pa-
tients. . . . The excitement in the field has shifted to
the elucidation of the genetic basis of the common
diseases.”1 And in the United States the director of the
National Human Genome Research Institute, Francis
Collins, has stated that the good that would come
from mapping the human genetic terrain “would in-
clude a new understanding of genetic contributions
to human disease and the development of rational
strategies for minimizing or preventing disease phe-
notypes altogether.”2
Statements like these clothe medicine in a genetic
mantle. The result of efforts to identify genes that
have a role in common diseases suggests a different
picture: the genetic mantle may prove to be like the
emperor’s new clothes. In this article we argue that
the new genetics will not revolutionize the way in
which common diseases are identified or prevented.
Mapping and sequencing the human genome will
lead to the identification of more genes causing men-
delian disorders and to the development of diagnos-
tic and predictive tests for them. The development
of safe and effective treatments, however, will usually
lag behind,3 although occasionally a treatment does
precede the discovery of the disease-causing allele, as
was the case for hemochromatosis.4 Furthermore, only
a small proportion of the population has mendelian
disorders, and this will limit the ultimate impact of
the Human Genome Project.
Our doubts stem from the incomplete penetrance
of genotypes for common diseases, the limited ability
to tailor treatment to genotypes, and the low mag-
nitude of risks conferred by various genotypes for
the population at large. Consequently, most people
will have little interest in learning their genotypes.
In the following sections, we use the term “geno-
type” to denote the alleles that a person possesses at
a single gene locus on homologous chromosomes. 
PENETRANCE
In contrast to genotypes for mendelian disorders
such as Huntington’s disease, which is due to a sin-
gle, highly penetrant autosomal dominant gene, most
genotypes for common, complex diseases are incom-
pletely penetrant, and correlations between the gen-
O
otype and the phenotype are therefore weak. Asso-
ciations between a disease and a genetic marker can
occur by chance,5,6 and some have proved to be spu-
rious.7-9 Although many disease-related genes have
been mapped to regions of specific chromosomes,
highly penetrant susceptibility-conferring genotypes
at loci related to asthma, hypertension, schizophrenia,
bipolar disorder, and other disorders have not been
found despite intensive efforts. 
Searches for susceptibility-conferring genotypes
for breast cancer,10 colon cancer,11 rare, early-onset
forms of type 2 diabetes,12 and Alzheimer’s disease13
have been successful, but in each case these geno-
types account for less than 3 percent of all cases.
One explanation is that the risk of disease conferred
by alleles at one locus depends not only on alleles at
other, independently segregating loci, which by them-
selves do not increase the risk,14,15 but also on envi-
ronmental factors.16 The problem of identifying sus-
ceptibility-conferring genotypes is compounded when
different combinations of gene loci are implicated in
a disease, for it means that finding enough patients
to serve as research subjects in a study will be ex-
tremely difficult.9,17
Frequently occurring genotypes, or polymorphisms
(frequency of 1 percent or more), are unlikely to have
a high penetrance for diseases that reduce reproduc-
tive fitness; such genotypes would be selected against
except when the presence of a gene on only one chro-
mosome (a single gene dose) confers a selective ad-
vantage that counterbalances the disadvantage of its
presence on both chromosomes (a double, or ho-
mozygous, gene dose). Polymorphisms may confer
higher risks for diseases that usually begin after the
reproductive years end (e.g., Alzheimer’s disease) or
diseases for which selection pressures have not had a
chance to reduce their frequency because the envi-
ronment or lifestyles have changed only in recent
generations. In populations that have been relatively
isolated, genotypes that confer susceptibility to dis-
eases with a recent increase in incidence may have
frequencies in the polymorphic range.18
TAILORING TREATMENTS TO GENOTYPES
A recent article in the New York Times echoed the
assertions of proponents of the genetic revolution:
“Health care will shift from a focus on detection and
treatment to a process of prediction and prevention.”19
One researcher was quoted as saying, “You can imag-
ine having an infant tested at birth . . . and a result
that says you are susceptible to diseases A, B, and
C.” Physicians will, the argument goes, be able to
tailor drugs to a patient’s genetic profile. 
Finding drugs to thwart a disease will depend on
the complexity of the genetic contribution to the dis-
ease. If genotypes at only one locus markedly increase
the risk of disease, drugs to compensate for the mal-
function could be devised. Yet, over 40 years have
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passed since the molecular basis of sickle cell anemia
was discovered,20 and no definitive treatment has
emerged. If genotypes at more than one locus must
be present simultaneously in order to increase the
risk of disease, finding the loci will be difficult. Once
they are found, a drug that blocks the effect of only
one allele might interrupt the pathogenic process, but
this remains to be proved.
Inherited differences in sensitivity to drugs may
be more amenable to pharmacologic tailoring than
differences in susceptibility to disease. Determining
patients’ genotypes before they are given certain drugs
may lead physicians to avoid administering drugs that
could be harmful or to lower the dosages in sensitive
patients, but the overall risk of adverse reactions may
not be very high because of the low penetrance or
low frequency of the genotypes. Alternatively, patients
could begin taking a drug, be carefully monitored,
and undergo genotyping only after an adverse reac-
tion has occurred. This approach has been recom-
mended for women in whom deep-vein thrombosis
develops while they are taking oral contraceptives and
who may have a susceptibility-conferring genotype
at the prothrombin gene locus.21
THE MAGNITUDE OF ABSOLUTE, 
RELATIVE, AND ATTRIBUTABLE RISKS
The lifetime risk of breast cancer is 12.6 percent for
women, the lifetime risk of prostate cancer is 15.9
percent for men, and the lifetime risk of colon can-
cer is 5.6 percent for men and women combined.22
The prevalence of asthma at all ages is 5.5 percent;
at the age of 45 to 64 years, the prevalence of ische-
mic heart disease is 5.2 percent and that of diabetes
is 5.8 percent.23 The lifetime risk of a major depres-
sive episode is 17.1 percent, and the lifetime risk of
nonaffective psychosis is 0.7 percent.24 We can use
these data together with genotype frequencies and
penetrance to calculate the relative risks of genotypes
that confer susceptibility. Thus, susceptibility-con-
ferring genotypes at the BRCA1 and BRCA2 gene
loci confer a relative risk of breast cancer of about
5.22,25 Susceptibility-conferring genotypes at DNA-
mismatch–repair gene loci confer a relative risk of co-
lon cancer of about 9.3.22,26 Susceptibility-conferring
genotypes with polymorphic frequencies would be ex-
pected to confer relative risks that are not much more
than 2 for various diseases.27 Given the high preva-
lences of these disorders, even a relative risk of 2 could
make the absolute risk conferred by susceptibility-
conferring genotypes appreciable, and people might
therefore flock to be tested for these genotypes.
Several other factors must be considered in the de-
cision whether or not to be tested. First, the proba-
bility that the disease will develop in a person with
a positive test result (the positive predictive value) is
approximately equal to the penetrance of the disease
and is usually low. As illustrated in Table 1, the pos-
itive predictive value is a function of the frequency
of a susceptibility-conferring genotype, the relative
risk of the disease, and the risk of disease in a given
population.28 Only if the frequency of the suscepti-
bility-conferring genotype is 1 percent or less and if
the relative risk approaches 20 will the positive pre-
dictive value exceed 50 percent when the risk of dis-
ease in a given population is 5 percent. When the
risk in a given population is lower, the positive pre-
dictive value will also be lower.
Second, the proportion of cases of a common dis-
ease that can be attributed to susceptibility-confer-
ring genotypes is small under the most likely cir-
cumstances (Table 2).29 Other factors, such as the
environment, can have a substantial role. Consequent-
ly, healthy people will gain little reassurance that a
negative test result means they will remain free of a
particular disease. For instance, only about 0.25 per-
cent of women carry BRCA1 or BRCA2 susceptibility-
conferring genotypes,30 and only about 0.1 percent
of people have susceptibility-conferring genotypes at
the DNA-mismatch–repair loci.31 Given the relative
risks associated with these susceptibility-conferring
genotypes, people who have them will account for
fewer than 5 percent of all patients with breast or co-
lon cancer. Only in the case of polymorphisms that
have frequencies in the range of 10 to 30 percent and
that increase susceptibility to disease is the attribut-
able risk appreciable. However, the risk of disease
conferred by polymorphic genotypes is usually low,
as we have already discussed (Table 1).
The I1307K allele at the adenomatous polyposis
coli (APC) gene locus, which is found in about 6 per-
cent of Ashkenazi Jews,32 and the apolipoprotein E
*The positive predictive value can be calculated with use of the following
formula: [R(D)¬100]÷[G(R¡1)+1], where R is the relative risk, D is
the incidence of a disease (in this case, 0.05), and G is the frequency of a
susceptibility-conferring genotype.
TABLE 1. POSITIVE PREDICTIVE VALUE OF TESTS 
FOR SUSCEPTIBILITY-CONFERRING GENOTYPES 
FOR A DISEASE WITH A LIFETIME RISK 
IN A GIVEN POPULATION OF 5 PERCENT.*
FREQUENCY OF 
SUSCEPTIBILITY-
CONFERRING GENOTYPE RELATIVE RISK
1.5 2.0 5.0 10.0 20.0
% positive predictive value (%)
0.1 7.5 10.0 24.9 49.6 98.1
0.5 7.5 10.0 24.5 47.8 91.3
1.0 7.5 9.9 24.0 45.9 84.0
10.0 7.1 9.1 17.9 26.3 34.5
30.0 6.5 7.7 11.4 13.5 14.9
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e4 allele, which is found in about 20 percent of a
predominantly white population,33 confer relative risks
of approximately 2 for colon cancer and Alzheimer’s
disease, respectively. According to the formula given
in Table 2, these alleles will account for 5.7 percent
of cases of colon cancer and 16.7 percent of cases of
Alzheimer’s disease, respectively, in the general pop-
ulation. When susceptibility-conferring genotypes at
two or more independent gene loci must be present
simultaneously for a disease to occur, the attribut-
able risk will be much smaller.
Third, only in the case of very few diseases are in-
terventions available that could prevent the disease in
healthy people with positive test results or that could
improve their survival or quality of life if the disease
eventually developed. No interventions based on the
identification of disease-related genes have yet proved
safe and effective. Approaches already in use, such as
prophylactic surgery and monitoring for incipient
disease, may prolong life in people with an inherited
susceptibility to breast and colon cancer, but the ex-
tent of improvement has not been established and
the effects on the quality of life have not been studied.
THE DEGREE OF PUBLIC INTEREST
IN LEARNING ABOUT DISEASE RISKS
Given the uncertainties surrounding test results and
the questionable effectiveness of interventions in per-
sons with positive results, how much interest will peo-
ple have in being tested or in making lifestyle chang-
es or undergoing medical or surgical interventions
that might reduce their risk of future disease? With
respect to predictive genetic testing, people want to
know the probability of their getting a disease if the
test result is positive (i.e., the positive predictive val-
ue) or negative (i.e., the false negative rate, calculat-
ed as 1¡sensitivity).34 When the test result is positive,
they also want to know what can be done to prevent
the disease or improve its outcome. Many people will
decide not to be tested if the positive predictive value
and sensitivity of a test are low35 and when no treat-
ment is available.36 Even when the positive predictive
value of a test is high and interventions are available,
as is the case for hereditary nonpolyposis colorectal
cancer, interest in testing has been lower than antic-
ipated.37 Interest is also influenced by how conven-
ient it is to be tested,35,38 raising questions about the
extent to which enthusiastic suppliers can manipu-
late demand.
Some evidence suggests that when risks have been
determined by genetic testing, persons perceive the
risks as less amenable to change,39 suggesting that
the likelihood that genetically based risk assessment
will result in behavioral changes is even lower than
the likelihood of this outcome after traditional as-
sessments of health risks. When medical or surgical
interventions are available, healthy people might not
want to undergo them. Most women with a family
history of breast cancer say they would not undergo
prophylactic mastectomy if they were found to have
a susceptibility-conferring genotype.40 When treat-
ment is not available for a specific disease, a few peo-
ple may want the information on risk just for the
sake of knowing and, possibly, planning. Finding out
that a test for highly penetrant genotypes is negative
may also reduce a person’s anxiety and the need for
other tests. For incompletely penetrant susceptibili-
ty-conferring genotypes, negative results may pro-
vide those tested with a false sense of security.
CONCLUSIONS
We do not want to downplay the importance of
highly penetrant susceptibility-conferring genotypes
or inherited drug sensitivity. Nonetheless, neither cat-
egory represents a large enough proportion of the
population to warrant widespread screening.41 Test-
ing in families with a history of the disease would
be a more efficient approach but does not a revolu-
tion make.
It would be revolutionary if we could determine
the genotypes of the majority of people who will get
common diseases. The complexity of the genetics of
common diseases casts doubt on whether accurate
prediction will ever be possible. Alleles at many dif-
ferent gene loci will increase the risk of certain dis-
eases only when they are inherited with alleles at
other loci, and only in the presence of specific en-
vironmental or behavioral factors. Moreover, many
combinations of predisposing alleles, environmental
factors, and behavior could all lead to the same
pathogenic effect.
In our rush to fit medicine with the genetic man-
tle, we are losing sight of other possibilities for im-
proving the public health. Differences in social struc-
*The attributable risk can be calculated with use of the following for-
mula: [G(R¡1)¬100]÷[G(R¡1)+1], where G is the frequency of a sus-
ceptibility-conferring genotype and R is the relative risk. The general for-
mula has been described previously.29
TABLE 2. PROPORTION OF CASES OF A DISEASE THAT CAN BE 
ATTRIBUTED TO A SUSCEPTIBILITY-CONFERRING GENOTYPE 
(THE ATTRIBUTABLE RISK).*
FREQUENCY OF 
SUSCEPTIBILITY-
CONFERRING GENOTYPE RELATIVE RISK
1.5 2.0 5.0 10.0 20.0
% attributable risk (%)
0.1 0.05 0.1 0.4 0.9 1.9
0.5 0.25 0.5 2.0 4.3 8.7
1.0 0.5 1.0 3.9 8.3 16.0
10.0 4.8 9.0 28.6 47.4 65.5
30.0 13.0 23.1 54.6 73.0 85.1
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ture, lifestyle, and environment account for much
larger proportions of disease42,43 than genetic differ-
ences. Although we do not contend that the genetic
mantle is as imperceptible as the emperor’s new
clothes were, it is not made of the silks and ermines
that some claim it to be. Those who make medical and
science policies in the next decade would do well to
see beyond the hype.
NEIL A. HOLTZMAN, M.D., M.P.H.
Johns Hopkins Medical Institutions
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